Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Proliferative Diabetic Retinopathy (PDR): later-stage trial registry

1 of 2 indexed Proliferative Diabetic Retinopathy (PDR) trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Proliferative Diabetic Retinopathy (PDR): 2 US clinical trials tracked, 1 recruiting.

Proliferative Diabetic Retinopathy (PDR) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Edward Wood, MD, running 1 of these trials.

Enrollment posture brief

Registry condition proliferative-diabetic-retinopathy-pdr

OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Proliferative Diabetic R (th…50%
Open-enrollment share among volume-matched conditions near Proliferative Diabetic Retinopathy (PDR)

Proliferative Diabetic Retinopathy (PDR) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Proliferative Diabetic Retinopathy (PDR) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Proliferative Diabetic Retinopathy (PDR) is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on Proliferative Diabetic Retinopathy (PDR) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Aflibercept 8mg Drug
1 trials
Panretinal Photocoagulation (PRP) Device
1 trials
Endolaser Device
1 trials
Vitrectomy Procedure
1 trials
Faricimab Drug
1 trials

US sites by state

Facility locations filed on Proliferative Diabetic Retinopathy (PDR) trials. A trial with sites in several states counts in each.

Texas 2 trials
Pennsylvania 1 trials
New York 1 trials
Missouri 1 trials
Minnesota 1 trials
Maryland 1 trials
Massachusetts 1 trials
Kentucky 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Proliferative Diabetic Retinopathy (PDR) page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Proliferative Diabetic Retinopathy (PDR) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Edward Wood, MD sponsors the most Proliferative Diabetic Retinopathy (PDR) trials on record, review their full trial history before evaluating a specific study. See Edward Wood, MD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Proliferative Diabetic Retinopathy (PDR) condition card totals 2 registered trials; most-linked intervention Aflibercept 8mg; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.